CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.49M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 6.6: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.52BUSDvs all stocks (USD)
Revenue (TTM)
5.49MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.17xvs all stocks
52-Week Change
58.86%vs all stocks
Market Capitalization
1.52BUSDvs all stocks (USD)
Enterprise Value
1.12BUSDvs all stocks (USD)
Forward P/E
-10.10xvs Biotechnology peers
Price to Book (MRQ)
3.92xvs Biotechnology peers
Enterprise to Revenue
204.73xvs Biotechnology peers
Enterprise to EBITDA
-7.39xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2792.32%vs Biotechnology peers
Return on Assets (TTM)
-23.82%vs Biotechnology peers
Return on Equity (TTM)
-47.05%vs Biotechnology peers
Revenue (TTM)
5.49MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0150USDUpdated Sep 28, 2026Gross Profit (TTM)
5.49MUSDvs all stocks (USD)
EBITDA (TTM)
-151.99MUSDvs all stocks (USD)
Net Income (TTM)
-149.63MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-132.19MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-80.97MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.77MUSDFY2025 · Dec 31, 2025Operating Income
-110.50MUSDvs all stocks (USD)
Pre-tax Income
-109.00MUSDFY2025 · Dec 31, 2025Net Income
-109.00MUSDFY2025 · Dec 31, 2025EBIT
-108.93MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-106.59MUSDFY2025 · Dec 31, 2025Research & Development
86.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
63.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-109.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-98.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-99.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
322.53MUSDFY2025 · Dec 31, 2025Interest Paid
5.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-109.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.15MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.63MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-153.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.77MUSDFY2025 · Dec 31, 2025Capital Expenditures
-738.00KUSDFY2025 · Dec 31, 2025Other Investing Activity
134.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-604.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
49.85MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-40.61MUSDFY2025 · Dec 31, 2025Other Financing Charges
-337.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
273.21MUSDFY2025 · Dec 31, 2025Shares Outstanding
325.30MSharesUpdated Sep 28, 2026Float Shares
232.62MSharesUpdated Sep 28, 2026Shares Short
51.41MSharesUpdated Sep 28, 2026Short Ratio
19.67daysvs all stocks
Short % of Shares Outstanding
16.03%vs all stocks
% Held by Insiders
9.45%vs all stocks
% Held by Institutions
94.03%vs all stocks
Total Cash (MRQ)
455.41MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.40USDUpdated Sep 28, 2026Total Debt (MRQ)
56.71MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1464xvs Biotechnology peers
Current Ratio (MRQ)
17.77xvs Biotechnology peers
Book Value per Share (MRQ)
1.19USDUpdated Sep 28, 2026Total Assets
343.32MUSDvs all stocks (USD)
Total Current Assets
324.65MUSDFY2025 · Dec 31, 2025Total Liabilities
96.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
18.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
26.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
319.77MUSDFY2025 · Dec 31, 2025Accounts Payable
6.28MUSDFY2025 · Dec 31, 2025Short-term Debt
1.86MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
777.00KUSDFY2025 · Dec 31, 2025Long-term Debt
68.28MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.55MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-711.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
246.94MUSDvs all stocks (USD)
52-Week Low
3.10USDUpdated Sep 28, 202652-Week High
7.30USDUpdated Sep 28, 202652-Week Change
58.86%vs all stocks
Beta
1.17xvs all stocks
50-Day MA
5.71USDUpdated Sep 28, 2026200-Day MA
5.48USDUpdated Sep 28, 2026Avg 10-Day Volume
4.99MSharesUpdated Sep 28, 2026Avg 30-Day Volume
3.17MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.4100USDUpdated Sep 28, 2026Other Income / Expense
-7.66MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.6: safe zoneNotable
Altman Z-Score: 6.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.49M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,485,000Global P5: 33,357,653.812
Market cap is $1.52B, above the global median of $1.18BNotable
Market cap (USD): 1,521,642,655Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
XGD Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Lingda Group Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets